Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | KHK | P50053 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 5/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31279350 | 1.00 | HTR1B (0.45) | HTR1BKHKBTKDRD3HRH3 | |
| SCHEMBL23711786 | 0.85 | HTR1B (0.48) | HTR1BKHKDRD3HRH3HRH1 | |
| SCHEMBL23711793 | 0.84 | HTR1B (0.47) | HTR1BKHKDRD4 | |
| SCHEMBL23711727 | 0.83 | KHK (0.41) | KHKBTKDRD3HRH3 | |
| SCHEMBL31280114 | 0.83 | KHK (0.41) | KHKBTKDRD3HRH3 | |
| SCHEMBL31279581 | 0.79 | GABRG2 (0.45) | KHK | |
| SCHEMBL31279229 | 0.79 | KHK (0.43) | KHKBTK | |
| SCHEMBL23711721 | 0.79 | GABRG2 (0.45) | KHK | |
| SCHEMBL23711748 | 0.79 | KHK (0.43) | KHKBTK | |
| SCHEMBL23711753 | 0.78 | KHK (0.70) | KHKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | KHK, GCK, FN3K | HTR1B 2359/4885KHK 1/4885BTK 1509/4885 |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | KHK, GCK, HK1 | HTR1B 1557/4885KHK 1/4885BTK 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.